Your browser doesn't support javascript.
Effectiveness of COVID-19 Vaccination Against SARS-CoV-2 Omicron Variant Infection and Symptoms - China, December 2022-February 2023.
Fu, Di; He, Guanhao; Li, Huanlong; Tan, Haomin; Ji, Xiaohui; Lin, Ziqiang; Hu, Jianxiong; Liu, Tao; Xiao, Jianpeng; Liang, Xiaofeng; Ma, Wenjun.
  • Fu D; Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou City, Guangdong Province, China.
  • He G; Disease Control and Prevention Institute, Jinan University, Guangzhou City, Guangdong Province, China.
  • Li H; Key Laboratory of Ministry of Education for Viral Pathogenesis & Infection Prevention and Control, Jinan University, Guangzhou City, Guangdong Province, China.
  • Tan H; Fuyang District Center for Disease Control and Prevention, Hangzhou City, Zhejiang Province.
  • Ji X; Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou City, Guangdong Province, China.
  • Lin Z; Key Laboratory of Ministry of Education for Viral Pathogenesis & Infection Prevention and Control, Jinan University, Guangzhou City, Guangdong Province, China.
  • Hu J; Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou City, Guangdong Province, China.
  • Liu T; Key Laboratory of Ministry of Education for Viral Pathogenesis & Infection Prevention and Control, Jinan University, Guangzhou City, Guangdong Province, China.
  • Xiao J; Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou City, Guangdong Province, China.
  • Liang X; Key Laboratory of Ministry of Education for Viral Pathogenesis & Infection Prevention and Control, Jinan University, Guangzhou City, Guangdong Province, China.
  • Ma W; Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou City, Guangdong Province, China.
China CDC Wkly ; 5(17): 369-373, 2023 Apr 28.
Article in English | MEDLINE | ID: covidwho-2294245
ABSTRACT
What is already known about this topic? A considerable percentage of the population has received both primary and booster vaccinations, which could potentially provide protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron infections and related symptoms. What is added by this report? The self-reported infection rate, as determined from an online survey, reached its peak (15.5%) between December 19 and 21, 2022, with an estimated 82.4% of individuals in China being infected as of February 7, 2023. During the epidemic, the effectiveness of booster vaccinations against SARS-CoV-2 Omicron infection was found to be 49.0% within three months of vaccination and 37.9% between 3 and 6 months following vaccination. Furthermore, the vaccine effectiveness of the booster vaccination in relation to symptom prevention varied from 48.7% to 83.2% within three months and from 25.9% to 69.0% between 3 and 6 months post-booster vaccination. What are the implications for public health practice? The development and production of efficacious vaccines, together with prompt vaccinations or emergency vaccinations, have the potential to mitigate the epidemic's impact and safeguard public health.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study Topics: Vaccines / Variants Language: English Journal: China CDC Wkly Year: 2023 Document Type: Article Affiliation country: Ccdcw2023.070

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study Topics: Vaccines / Variants Language: English Journal: China CDC Wkly Year: 2023 Document Type: Article Affiliation country: Ccdcw2023.070